The Dales Report – Why Psychedelic Treatments Will Benefit Investors and Healthcare Feb 27, 2023 The Dales Report – Why Psychedelic Treatments Will Benefit Investors and Healthcare
Radius Research Interview – Algernon NeuroScience Initiates TBI Research Program with DMT Feb 22, 2023 Radius Research Interview – Algernon NeuroScience Initiates TBI Research Program with DMT
Proactive Investors CEO Interview – Algernon NeuroScience completes first dosing in Phase 1 clinical study of DMT Feb 16, 2023 Proactive Investors CEO Interview – Algernon NeuroScience completes first dosing in Phase 1 clinical study of DMT
SR Times – “Drug Could Possibly Both Reduce Acute Damage of the Stroke” – How DMT Could be the Future of Stroke Treatment Feb 7, 2023 SR Times – “Drug Could Possibly Both Reduce Acute Damage of the Stroke” – How DMT Could be the Future of Stroke Treatment
Radius Research Interview – Algernon Pharmaceuticals (AGN) CEO Christopher J. Moreau – Ifendprodil Program Update Targeting Chronic Cough Jan 30, 2023 Radius Research Interview – Algernon Pharmaceuticals (AGN) CEO Christopher J. Moreau – Ifendprodil Program Update Targeting Chronic Cough
Radius Research – Algernon Pharma (AGN) CEO Chris Moreau – AP-188 DMT Dimethyltryptamine Program Update Jan 21, 2023 Radius Research – Algernon Pharma (AGN) CEO Chris Moreau – AP-188 DMT Dimethyltryptamine Program Update
Benzinga – A Psychedelic Program For Treatment Of Stroke: New Clinical Trial Begins Dosing Jan 18, 2023 Benzinga – A Psychedelic Program For Treatment Of Stroke: New Clinical Trial Begins Dosing
Microdose: Microdosing DMT to Treat Stokes: Not as Trippy as it Sounds Jan 17, 2023 Microdose: Microdosing DMT to Treat Stokes: Not as Trippy as it Sounds
Proactive Investors CEO Interview – Algernon NeuroScience Doses First Patient in Stroke Study Jan 17, 2023 Proactive Investors CEO Interview – Algernon NeuroScience Doses First Patient in Stroke Study
The Market Herald – Algernon Pharmaceuticals Announces Upcoming Phase 2b Chronic Cough Study of Ifenprodil Jan 10, 2023 The Market Herald – Algernon Pharmaceuticals Announces Upcoming Phase 2b Chronic Cough Study of Ifenprodil
Proactive Investors Interview – Algernon Pharmaceuticals Releases Details of Planned Phase 2b Chronic Cough Study of Ifenprodil Jan 9, 2023 Proactive Investors Interview – Algernon Pharmaceuticals Releases Details of Planned Phase 2b Chronic Cough Study of Ifenprodil
Benzinga – Psychedelic Subsidiaries News: Blackhawk Spins Out Three Companies, Algernon Creates A New One Jan 4, 2023 Benzinga – Psychedelic Subsidiaries News: Blackhawk Spins Out Three Companies, Algernon Creates A New One
Proactive Investors Interview – Algernon Pharmaceuticals Forms Algernon NeuroScience Subsidiary to Advance DMT Stroke Program Jan 4, 2023 Proactive Investors Interview – Algernon Pharmaceuticals Forms Algernon NeuroScience Subsidiary to Advance DMT Stroke Program
Wonderland 2022 Recap: Algernon Pharmaceuticals Dec 2, 2022 Wonderland 2022 Recap: Algernon Pharmaceuticals
The National Investor – Repurposing Drugs For New Needs — Algernon Pharmaceuticals Inc. (CSE-AGN; OTCQB-AGNPF) Nov 30, 2022 The National Investor – Repurposing Drugs For New Needs — Algernon Pharmaceuticals Inc. (CSE-AGN; OTCQB-AGNPF)
Psychedelic Therapeutics For Human Stroke: Participant Screening Expects To Begin Soon for Algernon Pharmaceuticals DMT Study Nov 21, 2022 Psychedelic Therapeutics For Human Stroke: Participant Screening Expects To Begin Soon for Algernon Pharmaceuticals DMT Study
MarketOne Video Interview with CEO Christopher J. Moreau – Algernon Pharmaceuticals is the First to Investigate DMT as a Treatment for Stroke Nov 17, 2022 MarketOne Video Interview with CEO Christopher J. Moreau – Algernon Pharmaceuticals is the First to Investigate DMT as a Treatment for Stroke
Psychedelic Finance – Feature: Christopher J. Moreau | Chief Executive Officer, Algernon Pharmaceuticals Nov 16, 2022 Psychedelic Finance – Feature: Christopher J. Moreau | Chief Executive Officer, Algernon Pharmaceuticals
Drug Discovery and Development – Why Algernon Believes it is the Janis Joplin of Psychedelic Medicine Companies Nov 4, 2022 Drug Discovery and Development – Why Algernon Believes it is the Janis Joplin of Psychedelic Medicine Companies
Psychedelic Finance – Feature: Algernon Pharmaceuticals Nov 3, 2022 Psychedelic Finance – Feature: Algernon Pharmaceuticals
Market One – Algernon Pharmaceuticals Receives Approval for Groundbreaking Phase 1 Study of DMT for Stroke Nov 3, 2022 Market One – Algernon Pharmaceuticals Receives Approval for Groundbreaking Phase 1 Study of DMT for Stroke
Born2Invest – Algernon Pharmaceuticals Is Developing Pioneering Treatments With a Cost-Efficient R&D Pipeline Oct 28, 2022 Born2Invest – Algernon Pharmaceuticals Is Developing Pioneering Treatments With a Cost-Efficient R&D Pipeline
BNN Bloomberg – In a sector ripe for revival, Algernon’s development pipeline positions it well. Oct 26, 2022 BNN Bloomberg – In a sector ripe for revival, Algernon’s development pipeline positions it well.
Radius Research – Algernon Pharmaceuticals (AGN) CEO Christopher J. Moreau: Yale Clinical Trial for DMT Phase 2 Depression Study Oct 25, 2022 Radius Research – Algernon Pharmaceuticals (AGN) CEO Christopher J. Moreau: Yale Clinical Trial for DMT Phase 2 Depression Study
Psychedelic Spotlight – Prolonged DMT Infusions could be a Breakthrough for Stroke Patients Oct 10, 2022 Psychedelic Spotlight – Prolonged DMT Infusions could be a Breakthrough for Stroke Patients
Drug Discovery and Development – DMT pioneer Rick Strassman weighs in on psychedelic hope and hype Oct 6, 2022 Drug Discovery and Development – DMT pioneer Rick Strassman weighs in on psychedelic hope and hype
High TImes – New Research Exploring DMT as a Treatment for Stroke Oct 5, 2022 High TImes – New Research Exploring DMT as a Treatment for Stroke
Radius Research – Algernon Pharmaceuticals (AGN) CEO Christopher J. Moreau: Business Update – Ifenprodil & DMT Trials Oct 3, 2022 Radius Research – Algernon Pharmaceuticals (AGN) CEO Christopher J. Moreau: Business Update – Ifenprodil & DMT Trials
Mugglehead Magazine – Algernon receives approval to conduct DMT study in the Netherlands Sep 26, 2022 Mugglehead Magazine – Algernon receives approval to conduct DMT study in the Netherlands
Pulmonary Fibrosis News – Orphan Drug Status Sought for NP-120 to Treat IPF With Cough Sep 24, 2022 Pulmonary Fibrosis News – Orphan Drug Status Sought for NP-120 to Treat IPF With Cough
Proactive Investors Interview – Algernon Pharmaceuticals Gains Approval for Phase 1 Clinical Study of DMT for Treatment of Stroke Sep 12, 2022 Proactive Investors Interview – Algernon Pharmaceuticals Gains Approval for Phase 1 Clinical Study of DMT for Treatment of Stroke
Streetwise Reports – Will Pharma Co. Keep Pushing Higher After Full Data Set Released on Lung Disease Study? Sep 5, 2022 Streetwise Reports – Will Pharma Co. Keep Pushing Higher After Full Data Set Released on Lung Disease Study?
Proactive Investors Interview – Algernon Pharmaceuticals Releases Positive Data from Study on Ifenprodil for IPF and Chronic Cough Sep 1, 2022 Proactive Investors Interview – Algernon Pharmaceuticals Releases Positive Data from Study on Ifenprodil for IPF and Chronic Cough
Streetwise Reports – Hedge Fund Doubles Position in Biotech Co. Aug 23, 2022 Streetwise Reports – Hedge Fund Doubles Position in Biotech Co.
MedicalGold.ca – Algernon Rapidly Advances Clinical Trials For Two Lead Programs Aug 17, 2022 MedicalGold.ca – Algernon Rapidly Advances Clinical Trials For Two Lead Programs
Pulmonary Fibrosis News – NP-120, Potential IPF Treatment, Stabilizes Lung Function in Trial Jul 20, 2022 Pulmonary Fibrosis News – NP-120, Potential IPF Treatment, Stabilizes Lung Function in Trial
